source · text/markdown
source_3af00958f7504263
sha256 0cb5628a4799db2e4027a6357125b0c890ff3fa2e26d87fd525a807dab22932e
by researka:v2 · 2026-05-28 00:25:26.145578+04:00
This synthesis tests the thesis that evidence for ACE inhibitors in aging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin-converting enzyme (ACE) inhibitors are among the most widely prescribed antihypertensives, yet whether they confer geroprotective benefits beyond blood-pressure control remains unresolved across aging-relevant outcomes including frailty, vascular stiffening, cognition, and longevity. The synthesis identified cross-study disagreements across outcome classes, with the most severe disagreements—mechanistic plausibility from preclinical frailty models versus null or mixed human-trial evidence—forming the central load-bearing question for the field. In our assessment, the weight of evidence favors a context-dependent rather than universal anti-aging profile for ACE inhibitors: mechanistic and preclinical plausibility is robust, but the functional tradeoff—demonstrated in the dissonance between mouse frailty attenuation and inconsistent human cognitive, cardiometabolic, and mortality outcomes—means that geroprotective claims currently outstrip the available high-certainty clinical proof. Future trials specifically designed with aging primary endpoints—functional capacity, multimorbidity trajectories, and mortality—rather than surrogate cardiovascular marke
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "e2ed1ed0-06c1-402d-9b45-0980a0f4b62a",
"title": "Research Synthesis: ACE inhibitors in aging \u2014 full paper"
}